Drug intelligence / Profile preview

A100S

Development stage: Unknown
Lead developer: TCRCure Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

A100S is an investigational CAR-T cell therapy developed by Guangdong Tcrcure Biopharma Technology. It is being studied primarily for the treatment of various neoplasms, including lung cancer, ovarian cancer, and testicular neoplasms. The drug is currently in Phase 1 clinical trials. Its mechanism of action involves chimeric antigen receptor T cells (CAR-T), which are engineered to target specific antigens on tumor cells, leading to their destruction. The therapy may also have potential applications in endocrinology and metabolic diseases as well as respiratory diseases[4].

Beyond the preview

Go deeper on A100S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A100S.

Explore the full profile